Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

From riociguat to mosliciguat: Giessen lung research advances new therapeutic principle for pulmonary vascular disease

Дата публикации: 24-09-2026 15:38:00

Promising Phase 2 results from the international PHocus study point to the potential of the investigational inhaled drug mosliciguat for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In 135 patients at 87 centers in 20 countries, mosliciguat achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 and significantly improved exercise capacity. The results support further clinical development, with a global Phase 3 trial in approximately 375 patients already underway.
Joint press release of the Institute for Lung Health (ILH) and the German Center for Lung Research (DZL)

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Von Riociguat zu Mosliciguat: Gießener Lungenforschung entwickelt neues therapeutisches Prinzip für pulmonale Gefäße014.5224-09-2026
2Un tratamiento obtiene resultados prometedores en hipertensión pulmonar01009-04-2026
3Rein Therapeutics RENEW Trial Enrollment Runs Ahead Of Schedule As R&D And G&A Spending Decline07.0615-08-2026
4Mukoviszidose: Dreifachtherapie im frühen Kindesalter besonders wirksam06.0824-09-2026
5Quarterly IL-6 antibody safely cuts inflammation in phase 2 study012.6316-09-2026
6DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study016.6705-05-2026
7STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study05.3310-08-2026
8Drug candidate treats severe fatty liver disease by protecting the gut in animal models2707-07-2026
9Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity2731-07-2025
10Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity7831-07-2025

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.38. Источник: idw-online.de.